
World Feb 28, 2021
U.K.’s variant trackers led the way. Now others are following.
The COVID-19 Genomics U.K. Consortium has become a global model for analyzing genomes for signs that the coronavirus is gaining power to spread — or to kill.
For James Paton's latest contributions to The Japan Times, see below:
The COVID-19 Genomics U.K. Consortium has become a global model for analyzing genomes for signs that the coronavirus is gaining power to spread — or to kill.
Dangerous coronavirus variants are carpeting the globe, pushing scientists in the U.K. and elsewhere to target multiple versions of the pathogen in a single shot.
Global gaps in access to vaccines are raising concerns that the spread of the virus will breed more dangerous versions of the pathogen, weakening medical weapons.
Even with the latest technologies, money and might behind the unprecedented global drive to knock out COVID-19, the disease is unlikely to be eliminated any time soon.
The encouraging late-stage trial results from Pfizer Inc. and Moderna Inc. set a high bar for rivals that are expected to follow soon with their own pivotal reports.
Fading trust in governments, political interference and the dash to create a shot in record time are sowing doubts.
After COVID-19’s emergence in Buenos Aires led to a strict lockdown in March, Juliana Cassataro and her fellow vaccine researchers grew concerned. The U.S., Europe and China had already revved up their quests to obtain shots; how far back in line would Argentina have ...
Wealthy countries have already locked up more than a billion doses of coronavirus vaccines, raising worries that the rest of the world will be at the back of the queue in the global effort to defeat the pathogen. Moves by the U.S. and U.K. to ...
When Michael Cohen showed up at Novartis AG last year proposing to help the drugmaker navigate the Donald Trump administration, it sounded like a promising opportunity. Cohen had, after all, served as an attorney for Trump and had close ties to the new president. It ...
Shares of Takeda Pharmaceutical Co. fell the most in nine years after the firm disclosed it is considering a bid for Shire PLC that could approach $50 billion (about ¥5.3 trillion), which would be the Japanese company’s biggest takeover ever. The decline in early Tokyo ...